At a glance: AOA-flagged ocular risks NAION (Non-Arteritic Anterior Ischemic Optic Neuropathy) Identified as a very rare but serious risk associated with semaglutide, the most prescribed GLP-1RA (Ozempic, Wegovy, Rybelsus) Up to 2 increased risk with semaglutide use After conducting risk assessment, the European Medicines Agency (EMA) calls for updated product info to list NAION as a very rare side effect Signs: Sudden, painless unilateral vision loss, visual field defect, dyschromatopsia, and optic disc swelling Discontinue GLP1RA and refer immediately if NAION is suspected Diabetic retinopathy (DR) progression In the SUSTAIN-6 trial, semaglutide users showed a higher rate of DR complications (3.0%) than placebo (1.8%) This may result from rapid HbA1c reduction, a known contributor to early DR worsening Especially concerning in patients with preexisting DR Perform a baseline dilated eye exam and follow up within 1218 months of treatment initiation Neovascular AMD A population-based study found GLP-1RA users had a 2 higher relative risk of developing wet AMD (0.2% vs 0.1%) Though absolute risk remains low, the potential impact is vision-threatening Closely monitor individuals with AMD risk factors or history Other rare events Isolated reports of: Uveitis Diplopia Optic neuropathies beyond NAION These are not yet confirmed by large-scale trials but suggest the need for comprehensive baseline evaluations
Semaglutide, Ozempic & Wegovy Manhattan telehealth care Receive care from home no routine office visits required for many eligible patients
10.1016/S0140-6736(20)30367-6 83 LizcanoF
Orforglipron is a once-daily, non-peptide oral GLP-1 receptor agonist from Eli Lilly
Furthermore, worsening of fibrosis was significantly reduced with liraglutide compared to placebo
Take 4 capsules daily with a glass of water4 to 6 hours before training to boost your energy levels during your sportin the morning rest daysIt takes some time to feel the effects of L-Carnitine on energy metabolism and recovery
